Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

NCT06053658 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06053658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06053658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 5, 2024
Completion date
November 1, 2028
Enrollment
48 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma